MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Last trade$4.06
Day change+$0.105 (+2.65%)
Day range$3.91 – $4.17
Volume2,135,623
Market cap$1.27B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.27B
Price / earnings
—
Price / book
-34.18×
Price / sales
3.08×
EV / sales
4.16×
EV / EBITDA
143.7×
Profitability
Earnings per share
-$0.23
Return on assets
-10.35%
Return on equity
200.78%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-13.04×
Current ratio
2.22×
Quick ratio
1.77×
Cash ratio
0.38×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$78.41M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MNKD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$101.87M
$109.37M
$90.17M
$111.96M
$82.13M
$76.53M
$78.35M
$76.78M
Cost of revenue
$23.51M
$29.54M
$17.47M
$29.67M
$20.2M
$20.57M
$17.52M
$19.6M
Gross profit
$78.36M
$79.83M
$72.7M
$82.28M
$61.93M
$55.96M
$60.84M
$57.17M
Selling, general and administrative
$61.41M
$58.3M
$54.09M
$58.41M
$29.09M
$31.62M
$25.01M
$23.97M
Research and development
$14.36M
$18M
$17.23M
$27.59M
$14.06M
$13.68M
$11.02M
$11.14M
Total operating expenses
$80.93M
$80.67M
$75.68M
$89.97M
$43.15M
$45.3M
$36.04M
$35.11M
Operating income
-$2.57M
-$836K
-$2.99M
-$7.69M
$18.78M
$10.66M
$24.8M
$22.06M
Interest expense
-$10.58M
-$14.82M
-$12.43M
-$13.87M
-$7.33M
-$6.19M
-$10.63M
-$7.48M
Income before taxes
-$23.17M
-$19.14M
-$16.37M
-$20.93M
$7.78M
$940K
$13.62M
$8.45M
Income taxes
$51K
-$106K
$253K
-$4.98M
-$204K
$272K
$459K
$1.02M
Net income
-$23.22M
-$19.03M
-$16.62M
-$15.95M
$7.99M
$668K
$13.16M
$7.42M
Net income attributable to common shareholders
-$23.22M
-$19.03M
-$16.62M
-$15.95M
$7.99M
$668K
$13.16M
$7.42M
EBITDA
$4.66M
$5.56M
$3.4M
-$1.66M
$20.84M
$12.75M
$26.91M
$24.22M
Basic earnings per share
-$0.07
-$0.06
-$0.05
-$0.05
$0.03
$0.00
$0.04
$0.03
Diluted earnings per share
-$0.07
-$0.06
-$0.05
-$0.05
$0.03
$0.00
$0.04
$0.03
Recent news
Company coverage with links to the original publishers.
MannKind reported Q3 2026 revenue of $101.87 million, up 24% year-over-year but missing the consensus estimate of $105.56 million by 3.5%. EPS of -$0.07 beat expectations of -$0.08 by 12.5%. Key revenue segments showed mixed results: commercial product sales surged 101.8% YoY but fell short of estimates, while Furoscix and Afrezza revenues underperformed analyst expectations. The stock has a Zacks Rank #3 (Hold) rating.
MannKind (MNKD) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.08 loss by 12.5%, with revenues of $101.87 million missing estimates by 3.5%. The stock has declined 30.7% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
MannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions.
MannKind Corporation announced new clinical data for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for heart failure and chronic kidney disease. Presented at the HFSA 2026 Annual Scientific Meeting, the data demonstrates comparable urine output to IV furosemide, consistent bioavailability across injection sites, and seamless transition capabilities from the previous On-body Infusor formulation. The product received FDA approval in July 2026 and is designed to enable earlier outpatient intervention for fluid overload management.
United Therapeutics announced FDA acceptance of its NDA for ralinepag, a once-daily oral prostacyclin receptor agonist for pulmonary arterial hypertension (PAH). The Phase III ADVANCE OUTCOMES study showed ralinepag reduced clinical worsening risk by 55% versus placebo and improved secondary endpoints. If approved in June 2027, it would be the first once-daily oral prostacyclin for PAH, complementing UTHR's existing PAH portfolio.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.